Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

HighTide Therapeutics / Equity Capital Markets

<ul>
<li>HighTide Therapeutics, a China-based clinical-stage biotechnology company, plans to raise up to US$200m via a Hong Kong listing.</li>
<li>In this note, we examine the company's core products, namely HTD1801, for the indication of NASH and T2DM.</li>
<li>We are not yet convinced of the product's prospects. We also think the management and pre-IPO investors are of mediocre quality.</li>
</ul>


HighTide Therapeutics, a China-based clinical-stage biotechnology company, plans to raise up to US$200m via a Hong Kong listing.
In this note, we examine the company's core products, namely HTD1801, for the indication of NASH and T2DM.
We are not yet convinced of the product's prospects. We also think the management and pre-IPO investors are of mediocre quality.


HighTide Therapeutics (君圣泰医药) Pre-IPO: Unconvincing Bet on NASH